After Hours Summary: APRE rises +15% on presentation of eprenetapopt data while CRCA falls -24% on CRL for VP-102 NDAAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: HRI +1.5% (raised FY21 adj. EBITDA guidance, provided targets for 2022, and outlined strategic initiatives), AXTA +0.9% (lowered Q3 net sales guidance and withdrew FY21 guidance)
Companies trading higher in after hours in reaction to news: APRE +15.3% (presented data from Phase 1/2 trial of eprenetapopt in advanced solid tumors), GMAB +5% (co and Seagen [SGEN] announced FDA accelerated approval for TIVDAK in previously treated recurrent or metastatic cervical cancer), OEG +4.5% (awarded new telecom project by Charter Communications [CHTR]), SDC +4.3% (plans to expand into France at start of Q4), SRAD +1.9% (announced that Michael Jordan will serve as a special advisor to co's board and is increasing his investment in co), SGEN +1.8% (co and Genmab [GMAB] announced FDA accelerated approval for TIVDAK), RDS.A +1.3% (agreed to sell Permian assets to ConocoPhillips [COP] for $9.5 bln), ROOT +1.2% (appointed Daniel Rosenthal as Chief Revenue and Operating Officer)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CFMS -7.1% (lowered product revs outlook for Q3), KAR -3.1% (withdrew FY21 guidance and provided long-term targets), LEN -2.3%
Companies trading lower in after hours in reaction to news: VRCA -24.1% (received Complete Response Letter from the FDA pertaining to VP-102 NDA for the treatment of molluscum contagiosum), ROLL -6.4% (announced offerings of common and mandatory convertible preferred stock)